title: Effective testosterone suppression for prostate cancer: is there a best castration therapy?
abstract: Achieving and maintaining effective suppression of serum testosterone levels in men treated with androgen ablation is one of the essential strategies in the management of prostate cancer. Historically, a serum testosterone below 50 ng/dL was considered to be the castrate level. Current data suggest that the new target for either surgical or chemical castration is a serum testosterone level of lower than 20 ng/dL in an attempt to maximize therapeutic outcomes. Testosterone breakthrough and the acute-on-chronic effects of administration of a luteinizing hormone-releasing hormone analogue may cause testosterone levels to periodically rise, sometimes to noncastrate levels. The goal of androgen ablation is to identify those agents that will most consistently achieve and maintain the lowest testosterone levels possible.
authors.affiliation: Department of Urology, Kimmel Cancer Center, Thomas Jefferson University Philadelphia, PA.
authors.forename: Leonard G
authors.initials: LG
authors.lastname: Gomella
references.citation: Lancet. 2000 Apr 29;355(9214):1491-8
references.pmid: 10801170
references.citation: J Urol. 2002 Feb;167(2 Pt 2):948-51; discussion 952
references.pmid: 11905923
references.citation: Urol Int. 2003;70(4):316-20
references.pmid: 12740498
references.citation: Urology. 2004 Dec;64(6):1177-81
references.pmid: 15596193
references.citation: N Engl J Med. 1989 Aug 17;321(7):419-24
references.pmid: 2503724
references.citation: Trends Endocrinol Metab. 2009 Jan;20(1):43-50
references.pmid: 19008119
references.citation: J Clin Endocrinol Metab. 1995 Nov;80(11):3209-22
references.pmid: 7593428
references.citation: Int J Gynaecol Obstet. 1980;18(5):318-24
references.pmid: 6110575
references.citation: BJU Int. 2007 Jan;99 Suppl 1:19-22; discussion 23-4
references.pmid: 17229164
references.citation: Scand J Urol Nephrol. 1992;26(1):11-4
references.pmid: 1631501
references.citation: Biochem Biophys Res Commun. 1975 Nov 17;67(2):576-82
references.pmid: 1106409
references.citation: Cancer. 1973 Nov;32(5):1126-30
references.pmid: 4585929
references.citation: Curr Opin Urol. 2000 Sep;10(5):415-20
references.pmid: 11005445
references.citation: Reprod Biomed Online. 2009 Jan;18(1):9-14
references.pmid: 19146763
references.citation: Lancet Oncol. 2006 Jun;7(6):472-9
references.pmid: 16750497
references.citation: Curr Opin Urol. 2009 May;19(3):322-6
references.pmid: 19318949
references.citation: Clin Cancer Res. 2007 Jan 1;13(1):241-5
references.pmid: 17200361
references.citation: Curr Med Res Opin. 2007 May;23(5):1077-80
references.pmid: 17519074
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):4027
references.pmid: 17606739
references.citation: N Engl J Med. 1998 Oct 8;339(15):1036-42
references.pmid: 9761805
references.citation: J Urol. 2002 Sep;168(3):1001-4
references.pmid: 12187208
references.citation: Urol Int. 1998;60(1):33-40
references.pmid: 9519419
references.citation: Urology. 2000 Dec 20;56(6):1021-4
references.pmid: 11113751
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1596-605
references.pmid: 17404365
references.citation: Cleve Clin J Med. 2007 May;74 Suppl 3:S38-46
references.pmid: 17549824
references.citation: J Urol. 2000 Sep;164(3 Pt 1):726-9
references.pmid: 10953134
references.citation: Eur Urol. 2006 Jan;49(1):54-8; discussion 58
references.pmid: 16314038
references.citation: BJU Int. 2003 Aug;92(3):226-31
references.pmid: 12887472
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3984-90
references.pmid: 16921051
references.citation: Clin Genitourin Cancer. 2007 Sep;5(6):371-8
references.pmid: 17956709
references.citation: Urology. 1994 Jun;43(6):834-7
references.pmid: 8197647
references.citation: BJU Int. 2008 Dec;102(11):1531-8
references.pmid: 19035858
references.citation: JAMA. 2005 Jul 13;294(2):238-44
references.pmid: 16014598
references.citation: N Engl J Med. 1997 Jul 31;337(5):295-300
references.pmid: 9233866
references.citation: J Urol. 2007 Oct;178(4 Pt 1):1290-5
references.pmid: 17698136
references.citation: J Urol. 1997 Oct;158(4):1623-4
references.pmid: 9302187
references.citation: Urology. 2009 May;73(5 Suppl):S28-35
references.pmid: 19375624
references.citation: Prostate Cancer Prostatic Dis. 2009;12(1):88-93
references.pmid: 18574490
references.citation: J Urol. 2002 Feb;167(2 Pt 1):535-8
references.pmid: 11792913
references.citation: J Urol. 1973 May;109(5):858-60
references.pmid: 4699685
references.citation: Urology. 2001 Aug;58(2 Suppl 1):5-9
references.pmid: 11502435